Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

READ MORE

LATEST NEWS

June 3, 2019
Sirnaomics Counts on New RNA Technology to Fuel Wide-Ranging Cancer & Fibrosis Pipeline While some RNA technology companies are still exploring the accompanying science, Sirnaomics, based in Gaithersburg... READ MORE
May 28, 2019
Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer Mr. Shaw is a highly regarded biopharmaceutical executive and board member with more than twenty... READ MORE
May 16, 2019
Sirnaomics Publishes Data for Lead Candidate STP705 in Cancer Model as 2019 ASCO Abstract Sirnaomics announced the results showing STP705 inhibits the growth of HuCCt-1 (a human cholangiocarcinoma cell... READ MORE
April 26, 2019
Sirnaomics Closes $47 Million Series C Financing to Develop RNAi Therapeutics Sirnaomics has sealed the C2 round of financing for $22 million. This round of funding... READ MORE
April 8, 2019
Sirnaomics to Present at World Orphan Drug Congress 2019 Sirnaomics announced that the Company's management will present its platform technology and discuss the potential... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Read More

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...

Read More
U.S.A  •  China
© 2007-2019 by Sirnaomics, Inc.
Contact